Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure

Clinical Microbiology and Infection(2021)10.1016/j.cmi.2020.12.032Source: DataRank Database

Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure is a research paper published in Clinical Microbiology and Infection (2021). On theSindex it has a DataRank of 0. It has been cited 27 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access27 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.81)OA: bronzeTopics (33)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Marc Lipsitch ORCID,Nir Eyal ORCID

Live enrichment

PubMed:33421580 PMC:PMC7787506 OpenAlex:https://openalex.org/W3092233007

National Institute of General Medical Sciences

Grant: U54GM088558

National Institute of Allergy and Infectious Diseases

Grant: AI114617-01A1

National Science Foundation

Grant: 2039320

NIAID NIH HHS

Grant: R01 AI114617

Open Philanthropy Project

National Science Foundation

National Institute of General Medical Sciences

National Institutes of Health

FWCI

0.81

Citation Percentile

0.7%

Citation Trend

2021

2022

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.clinicalmicrobiologyandinfection.com/article/S1198743X20307928/pdf

publisherhttp://www.clinicalmicrobiologyandinfection.com/article/S1198743X20307928/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1198743X20307928?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1198743X20307928?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cmi.2020.12.032

Fields of Study

SARS-CoV-2 and COVID-19 ResearchStatistical Methods in Clinical TrialsSARS-CoV-2 detection and testing

MeSH Terms

COVID-19SARS-CoV-2COVID-19 VaccinesClinical Trials as TopicHumansResearch DesignSafetyTime Factors

Keywords

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Clinical trial2019-20 coronavirus outbreakIntensive care medicineMedicineClinical study designSet (abstract data type)Vaccine efficacyComputer scienceVirologyRisk analysis (engineering)VaccinationInfectious disease (medical specialty)PathologyDiseaseVaccinesRandomized controlled trialsCoronavirusEthicsResearch DesignHuman Challenge Studies

Sustainable Development Goals

SDG 0: Partnerships for the goals

Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure

FAIR Checklist

Authors (2)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)